We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+8.93%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.4B
AUM Growth
-$406M
Cap. Flow
-$163M
Cap. Flow %
-1.13%
Top 10 Hldgs %
24.27%
Holding
957
New
98
Increased
341
Reduced
353
Closed
82

Top Buys

Rank Stock Value
1
BZ icon
Kanzhun
BZ
+$45.9M
2
STKL
SunOpta
STKL
+$45M
3
ZTO icon
ZTO Express
ZTO
+$44.4M
4
JPM icon
JPMorgan Chase
JPM
+$39.9M
5
XIFR
XPLR Infrastructure LP
XIFR
+$36.1M

Top Sells

Rank Stock Value
1
MELI icon
Mercado Libre
MELI
+$79.9M
2
MSFT icon
Microsoft
MSFT
+$58.5M
3
VERU icon
Veru
VERU
+$53.9M
4
PG icon
Procter & Gamble
PG
+$50.5M
5
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$37M

Sector Composition

Rank Sector Weight
1 Healthcare 30.95%
2 Technology 26.5%
3 Financials 9.1%
4 Consumer Discretionary 8.02%
5 Industrials 7.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SRE icon
301
Sempra
SRE
$58.1B
$7.28M 0.05%
104,694
+11,622
+12% +$892K
FOLD
302
DELISTED
Amicus Therapeutics
FOLD
$7.08M 0.05%
693,879
IPG
303
DELISTED
Interpublic Group of Companies
IPG
$7M 0.05%
204,180
-237,703
-54% -$8.54M
SLB icon
304
SLB Ltd
SLB
$72.7B
$6.98M 0.05%
154,472
+28,735
+23% +$1.53M
CCI icon
305
Crown Castle
CCI
$34.6B
$6.95M 0.05%
56,395
+932
+2% +$129K
BLK icon
306
Blackrock
BLK
$167B
$6.9M 0.05%
11,197
+620
+6% +$437K
KRYS icon
307
Krystal Biotech
KRYS
$10.7B
$6.78M 0.05%
+92,000
New +$7.23M
PCRX icon
308
Pacira BioSciences
PCRX
$1.04B
$6.76M 0.05%
179,901
-45,000
-20% -$1.79M
SHW icon
309
Sherwin-Williams
SHW
$83.5B
$6.74M 0.05%
32,555
-9,765
-23% -$2.23M
ARWR icon
310
Arrowhead Research
ARWR
$12.1B
$6.73M 0.05%
288,054
-70,000
-20% -$2.2M
DYN icon
311
Dyne Therapeutics
DYN
$4.68B
$6.72M 0.05%
633,624
IDXX icon
312
Idexx Laboratories
IDXX
$44.9B
$6.67M 0.05%
14,490
-2,251
-13% -$1.08M
BEPC icon
313
Brookfield Renewable
BEPC
$5.86B
$6.62M 0.05%
206,101
+197,390
+2,266% +$5.98M
TU icon
314
Telus
TU
$17.4B
$6.6M 0.05%
361,735
+321,779
+805% +$6.54M
ACET icon
315
Adicet Bio
ACET
$77.6M
$6.53M 0.05%
76,923
CPNG icon
316
Coupang
CPNG
$27.2B
$6.5M 0.05%
441,600
-1,358,764
-75% -$21.1M
NTRA icon
317
Natera
NTRA
$36.4B
$6.35M 0.04%
124,163
+69,163
+126% +$3.32M
RHI icon
318
Robert Half
RHI
$4.11B
$6.3M 0.04%
84,947
-56,927
-40% -$4.52M
AVY icon
319
Avery Dennison
AVY
$12.8B
$6.27M 0.04%
38,047
-9,111
-19% -$1.66M
HIG icon
320
Hartford Financial Services
HIG
$39.9B
$6.24M 0.04%
97,268
+36,746
+61% +$2.73M
DXCM icon
321
DexCom
DXCM
$29B
$6.21M 0.04%
58,028
+1,462
+3% +$164K
BX icon
322
Blackstone
BX
$104B
$6.2M 0.04%
76,638
+42,219
+123% +$3.73M
COF icon
323
Capital One
COF
$128B
$6.17M 0.04%
69,672
+24,439
+54% +$2.56M
OSH
324
DELISTED
Oak Street Health, Inc.
OSH
$6.11M 0.04%
+171,495
New +$5.54M
SYF icon
325
Synchrony
SYF
$24.4B
$6.07M 0.04%
226,624
-52,991
-19% -$1.78M

Similar funds

Candriam SCA's Q1 2023 Portfolio in Review

As of Q1 2023, Candriam SCA held 957 positions worth $14.4B, down 2.7% from $14.8B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Candriam SCA's Q1 2023 filing shows 98 new, 341 increased, 353 reduced and 82 closed positions. Its largest new stake was Kanzhun: 2,106,130 shares worth $36.9M. The largest sale was Mercado Libre, an estimated $79.9M.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 33% a quarter earlier, followed by Technology and Financials.

  • Candriam SCA's largest Q1 2023 buy was Kanzhun: 2,106,130 shares worth $36.9M.
  • Candriam SCA added most to SunOpta in Q1 2023, an estimated $45M increase.
  • Candriam SCA's biggest Q1 2023 reduction was Mercado Libre, cutting an estimated $79.9M.
  • Candriam SCA fully exited Veru in Q1 2023, selling an estimated $53.9M.
  • Candriam SCA's ten largest holdings make up 24% of its $14.4B portfolio in Q1 2023.
  • Candriam SCA opened 98 new positions and closed 82 in Q1 2023.
  • Candriam SCA's portfolio value fell 2.7% quarter-over-quarter to $14.4B.

Based on Candriam SCA's 13F filing for Q1 2023, filed 12 May 2023.